Narratiive Tags - Khaleej Times Desktop
Coronavirus Pandemic
Logo
 

India's Hetero Labs, Cipla get approval to make Gilead's Covid-19 drug remdesivir

Reuters
Filed on June 22, 2020 | Last updated on June 22, 2020 at 03.12 pm
Hetero Labs, Cipla, Gilead, remdesivir, covid-19, coronavirus, Covifor, Cipremi

(Reuters)

Gilead signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its Covid-19 treatment.

India's drug regulator has given Hetero Labs and Cipla Ltd the green light to manufacture and market their generic version of Gilead Sciences Inc's experimental Covid-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.

The drug, which will be marketed under the brand name Covifor, will likely be priced at Rs5,000-6,000 rupees for a 100 milligram dose, Hetero said.

India's Cipla said its generic version of remdesivir will be called Cipremi.

The Drug Controller General of India (DCGI) was not immediately available for comment.

Gilead Sciences Inc signed non-exclusive licensing pacts last month with five generic drugmakers based in India and Pakistan to expand the supply of its Covid-19 treatment.

The pacts allow Jubilant Life Sciences Ltd, Cipla, Hetero Labs, Mylan NV and Ferozsons Laboratories Ltd to make and sell the drug in 127 countries.

Indian drugmaker Zydus Cadila said last week it signed a non-exclusive licensing pact with Gilead Sciences to manufacture and market remdesivir.


ERROR: Macro /ads/dfp-ad-article-new is missing!
MORE FROM Coronavirus Pandemic
MORE FROM Khaleej Times
CurrentRequestUnmodified: /apps/pbcs.dll/article?AID=/20200702/ARTICLE/200709802&Show=0 macro_action: article, macro_profile: , macro_adspot:
 
 
 
 
 
 
KT App Download
khaleejtimes app

All new KT app
is available
for download:

khaleejtimes - android khaleejtimes - ios khaleejtimes - HUAWEI AppGallery